Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada
J Amdahl, J Diaz, J Park, HR Nakhaipour, TE Delea - Current Oncology, 2016 - mdpi.com
Background: In Canada and elsewhere, pazopanib and sunitinib—tyrosine kinase inhibitors
targeting the vascular endothelial growth factor receptors—are recommended as first-line …
targeting the vascular endothelial growth factor receptors—are recommended as first-line …
[HTML][HTML] Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces
DTS Woon, T Chandrasekar, L Aaron… - Canadian Urological …, 2018 - ncbi.nlm.nih.gov
Methods We describe provincial differences in access to approved mCRPC therapies. Data
sources include the pan-Canadian Oncology Drug Review database, provincial cancer care …
sources include the pan-Canadian Oncology Drug Review database, provincial cancer care …
Variation and consternation: access to unfunded cancer drugs in Canada
SR Berry, WK Evans, EL Strevel… - Journal of oncology …, 2012 - ascopubs.org
Purpose: New anticancer drugs are improving outcomes for patients with cancer but at
significant cost, and some publically funded health care systems have chosen not to fund …
significant cost, and some publically funded health care systems have chosen not to fund …